Trial Profile
A pilot study to investigate whether adding maraviroc to existing therapy has any effect for people with HIV and fatty liver disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2023
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms HEPMARC
- 26 Oct 2022 Results assessing feasibility of add-on maraviroc in people with well-controlled HIV and NAFLD presented at the 16th International Congress on Drug Therapy and HIV Infection
- 03 Feb 2022 Status changed from active, no longer recruiting to completed.
- 08 Oct 2020 Results presented at the 15th International Congress on Drug Therapy and HIV Infection